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OBJECTIVE — To investigate the relation between serum concentration of 25-
hydroxyvitamin D [25(OH)D] and insulin action and secretion.
RESEARCH DESIGN AND METHODS — In a cross-sectional study of 446 Pan-
European subjects with the metabolic syndrome, insulin action and secretion were assessed by
homeostasis model assessment (HOMA) indexes and intravenous glucose tolerance test to cal-
culate acute insulin response, insulin sensitivity, and disposition index. Serum 25(OH)D was
measured by high-performance liquid chromatography/mass spectrometry.
RESULTS — The 25(OH)D3 concentration was 57.1  26.0 nmol/l (mean  SD), and only
20% of the subjects had 25(OH)D3 levels 75 nmol/l. In multiple linear analyses, 25(OH)D3
concentrations were not associated with parameters of insulin action or secretion after adjust-
ment for BMI and other covariates.
CONCLUSIONS — In a large sample of subjects with the metabolic syndrome, serum con-
centrations of 25(OH)D3 did not predict insulin action or secretion. Clear evidence that D
vitamin status directly inﬂuences insulin secretion or action is still lacking.
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L
ow serum concentrations of 25-
hydroxyvitamin D [25(OH)D] have
been linked to disturbances in glu-
cose metabolism (1–3), development of
type 2 diabetes (4), and increased risk of
the metabolic syndrome (5–7). To ex-
plore the associations between serum
concentrations of 25(OH)D and glucose
metabolism, we evaluated the relation-
shipbetween25(OH)Dstatusandinsulin
secretion and action estimated both by
the homeostatic model assessment
(HOMA) and intravenous glucose toler-
ance test (IVGTT) in a large sample of Eu-
ropean subjects with the metabolic
syndrome.
RESEARCH DESIGN AND
METHODS— Cross-sectional data
were obtained from baseline assessment
of 446 Caucasian subjects, aged 35–70
years, BMI 20–40 kg/m
2, recruited for
theLIPGENEstudy(NCT00429195)per-
formed in eight European countries in
2005 and 2006. All subjects had the met-
abolicsyndromedeﬁnedbythreeormore
slightly modiﬁed National Cholesterol
Education Program (NCEP) Adult Treat-
ment Panel (ATP)-III criteria (8): levels of
fasting plasma glucose5.5 mmol/l, trig-
lycerides 1.5 mmol/l, HDL cholesterol
1.0 mmol/l (males) or1.3 mmol/l (fe-
males), blood pressure 130/85 mmHg
or on blood pressure–lowering medica-
tion, and waist circumference 102 cm
(males) or 88 cm (females). The study
was approved by local ethics committees
at each center (Dublin, Reading, Oslo,
Marseille, Maastricht, Cordoba, Krakow,
and Uppsala) and conﬁrmed to the Dec-
laration of Helsinki. All participants gave
written informed consent.
Aquestionnairewasusedtoassessthe
level of physical activity (9), smoking
habits, alcohol consumption, and demo-
graphic data. Anthropometric and blood
pressure measurements were recorded
according to standard protocols. An insu-
lin-modiﬁedIVGTTwasperformedasde-
scribed earlier (10). Measures of insulin
sensitivity (Si) were obtained using the
MINMOD Millennium Program (version
6.02, Richard N. Bergman) (11). The
acute insulin response to glucose (AIR)
wasdeﬁnedastheincrementalareaunder
the curve from 0 to 8 min. Disposition
index was calculated as AIR  Si. HOMA
indexes (HOMA2, version 2.2.2 http://
www.dtu.ox.ac.uk/index.php?maindoc/
homa) were used to assess insulin
resistance (HOMA-IR) and -cell func-
tion (HOMA-) from fasting blood
samples (12). Vitamin 25(OH)D2 and
25(OH)D3 were analyzed with high-per-
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spectrometry. Only 15 subjects (3%) had
measurable concentrations of 25(OH)D2,
mean 10.1 nmol/l, range 6.5–24.6
nmol/l. Including 25(OH)D2 in the anal-
yses did not inﬂuence the result. All ex-
aminations were performed in January/
February to avoid seasonal variation.
Correlations between parameters were
calculated with Pearson’s or Spearman’s
correlation coefﬁcient as appropriate.
Non–normally distributed data were
transformed using logarithmic function.
Multiple linear regression models were
used to assess the relationship of
25(OH)D3 with Si, AIR, disposition in-
dex, HOMA-, and HOMA-IR, respec-
tively.Statisticalanalyseswereperformed
using SPSS for Windows, version 16.0. P
values 0.05 (two-sided) were regarded
as statistically signiﬁcant.
RESULTS— Serum concentration of
25(OH)D3 was 57.1  26.0 nmol/l
(mean  SD), range 13.7–170.4 nmol/l.
Only 91 (20%) subjects had levels 75
nmol/l, and a majority (n  227) had bio-
chemical vitamin D deﬁciency (50
nmol/l)(13).Subjectcharacteristicsarepre-
sented across tertiles of serum 25(OH)D3
concentration(supplementalTable1,avail-
able in an online-only appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1692/DC1).
In unadjusted analyses, IVGTT-
derived parameters did not differ across
tertiles of 25(OH)D3, whereas fasting in-
sulin, HOMA-IR, and HOMA- were sig-
niﬁcantly different (all P  0.015), with
highervaluesamongsubjectsinthelower
tertile of 25(OH)D3 concentration (sup-
plemental Table 2). Serum levels of
25(OH)D3correlatednegativelywithBMI
(r0.28,P0.001),AIR(r0.11,
P  0.033), fasting insulin (r  0.14,
P  0.002), HOMA-IR (r  0.14, P 
0.003), and HOMA- (r  0.15, P 
0.001), but not with Si(r0.062, P0.21)
or disposition index (r  0.059, P 
0.24). In a multivariate regression analy-
sis including potential covariates (Table
1), serum 25(OH)D3 concentration was a
statistically signiﬁcant predictor of
HOMA-IR,HOMA-,andAIR(P0.05)
but not of Si or disposition index when
adjusting for sex, age, and geographic lo-
cation. After adding BMI to the regression
model, neither HOMA indexes nor AIR
were signiﬁcantly associated with
25(OH)D3 (Table 1).
To further explore these relation-
ships,wecomparedsubjectswithasevere
biochemical vitamin D deﬁciency (25
nmol/l,n20)tosubjectswithsufﬁcient
vitamin D status (75 nmol/l, n  91).
Only BMI was signiﬁcantly different be-
tween groups (P  0.001), whereas
HOMA and IVGTT parameters were not.
CONCLUSIONS— Wefoundnosig-
niﬁcant associations between IVGTT-
derived parameters of insulin secretion
and action and serum 25(OH)D3 concen-
trations. At variance with our ﬁndings,
Chiu et al. (2) observed a positive associ-
ation between vitamin D status and insu-
lin sensitivity in 126 glucose-tolerant
students investigated by hyperglycemic
clamp,remainingsigniﬁcantalsoafterad-
justment for BMI. The reason for the dif-
ferent results between this study and ours
mightbethedifferencesinpopulationsor
methodsusedtoassessinsulinsensitivity.
In the former study, there were also in-
verserelationshipsbetweenﬁrst-andsec-
ond-phase insulin secretion and serum
25(OH)D concentrations that were not
signiﬁcant after adjusting for covariates,
in accordance with our results.
A signiﬁcant relationship between
25(OH)D and fasting insulin and
HOMA-IR has been reported by others
(1,14,15). The reason for the differences
betweentheseandourresultsmaybethat
we investigated a more homogeneous
group of subjects that all had the meta-
bolicsyndromeandhencesomedegreeof
insulin resistance. We speculate that vita-
min D status may be more closely associ-
ated with hepatic insulin sensitivity
reﬂected by fasting glucose and insulin
levels than with peripheral insulin sensi-
tivity, as measured by IVGTT. Thus, the
link between vitamin D status and tissue-
speciﬁc insulin action requires further
investigation.
Strengths of our study included the
use of IVGTT with minimal modeling to
assess insulin secretion and insulin ac-
tion. This extends the knowledge from
previous investigations that mostly
were based on fasting blood samples.
Furthermore, the inclusion of subjects
from eight different centers across Eu-
rope and limiting the data sampling to 2
months of the year also are advanta-
geous. Limitations of the study were
that we only investigated one ethnic
group of individuals and that rather few
had severe vitamin D deﬁciency. Also,
since the presence of metabolic syn-
drome was an inclusion criterion for
participation in the study, cross-
sectional relationships may be attenu-
ated in our population.
In conclusion, we found no correla-
tions between vitamin 25(OH)D3 and
IVGTT-basedestimatesofinsulinaction
and secretion in this large sample of
subjects with the metabolic syndrome.
Prospective and interventional studies
using reliable techniques are needed to
further elucidate the relation between
25(OH)D and insulin action and
secretion.
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HOMA-IR 0.004 0.002 0.016 0.002 0.002 0.19 0.002 0.002 0.24
HOMA- (%) 0.185 0.067 0.007 0.128 0.066 0.063 0.113 0.068 0.070
*Model 1: adjusted for age, sex, and geographic location. †Model 2: further adjusted for BMI. ‡Model 3: further adjusted for education, smoking, alcohol
consumption, and use of vitamin supplements.
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